Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
Summary
“ Today’s announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eye care professionals to better address the evolving needs of their patients,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “ ELIOS provides a tissue-friendly, precision non-thermal laser-based and highly adoptable procedure for the treatment of glaucoma,” said Professor Ike K. Ahmed, MD, University of Toronto and Moran Eye Center. “ The synergy between cataract surgery and MIGS can help ophthalmologists provide streamlined care and improve patient quality of life.” “ Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help change the treatment paradigm for the estimated 80 million people worldwide living with glaucoma,” said Elliot Friedman, former Elios Vision chairman and CEO. “ The goal is to make combining cataract and glaucoma treatment the new standard of care, and that’s even more attainable given Bausch + Lomb’s presence in nearly 100 countries.” The ELIOS technology, which is CE marked, is currently marketed and sold in the European Union. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries.